[go: up one dir, main page]

TNSN05042A1 - Association synergique d'un ligand de alpha -2- delta et d'un inhibiteur de pdev pour une utilisation dans le traitement de la douleur - Google Patents

Association synergique d'un ligand de alpha -2- delta et d'un inhibiteur de pdev pour une utilisation dans le traitement de la douleur

Info

Publication number
TNSN05042A1
TNSN05042A1 TNP2005000042A TNSN05042A TNSN05042A1 TN SN05042 A1 TNSN05042 A1 TN SN05042A1 TN P2005000042 A TNP2005000042 A TN P2005000042A TN SN05042 A TNSN05042 A TN SN05042A TN SN05042 A1 TNSN05042 A1 TN SN05042A1
Authority
TN
Tunisia
Prior art keywords
alpha
pain
treatment
delta ligand
pdev inhibitor
Prior art date
Application number
TNP2005000042A
Other languages
English (en)
Inventor
Mark John Field
Richard Griffith Williams
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN05042A1 publication Critical patent/TNSN05042A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une association d'un ligand de alpha-2-delta et d'un inhibiteur de PDEV pour une utilisation en thérapie, en particulier dans le traitement curatif, prophylactique ou palliatif de la douleur, en particulier de la douleur neuropathique. Des ligands de alpha-2-delta particulièrement appréciés sont la gabapentine et la prégabaline. Des inhibiteurs de PDEV particulièrement appréciés sont le sildénafil, le vardénafil et le tadalafil.
TNP2005000042A 2002-08-15 2005-02-15 Association synergique d'un ligand de alpha -2- delta et d'un inhibiteur de pdev pour une utilisation dans le traitement de la douleur TNSN05042A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219024.7A GB0219024D0 (en) 2002-08-15 2002-08-15 Synergistic combinations
PCT/IB2003/003476 WO2004016259A1 (fr) 2002-08-15 2003-08-04 Combinaison synergique d'un ligand alpha-2-delta et d'un inhibiteur de pdev destinee a traiter la douleur

Publications (1)

Publication Number Publication Date
TNSN05042A1 true TNSN05042A1 (fr) 2007-05-14

Family

ID=9942388

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000042A TNSN05042A1 (fr) 2002-08-15 2005-02-15 Association synergique d'un ligand de alpha -2- delta et d'un inhibiteur de pdev pour une utilisation dans le traitement de la douleur

Country Status (40)

Country Link
EP (1) EP1536782B1 (fr)
JP (1) JP2006502139A (fr)
KR (2) KR20050042154A (fr)
CN (1) CN1674884A (fr)
AP (1) AP2005003227A0 (fr)
AR (1) AR040871A1 (fr)
AT (1) ATE359775T1 (fr)
AU (1) AU2003249476B2 (fr)
BR (1) BR0313484A (fr)
CA (1) CA2495433A1 (fr)
CR (1) CR7687A (fr)
DE (1) DE60313330T2 (fr)
DK (1) DK1536782T3 (fr)
EA (1) EA007504B1 (fr)
EC (1) ECSP055593A (fr)
ES (1) ES2285230T3 (fr)
GB (1) GB0219024D0 (fr)
GE (1) GEP20084366B (fr)
GT (1) GT200300173A (fr)
HN (1) HN2003000247A (fr)
HR (1) HRP20050136A2 (fr)
IL (1) IL166415A0 (fr)
IS (1) IS7643A (fr)
MA (1) MA27381A1 (fr)
MX (1) MXPA05001835A (fr)
NO (1) NO20050782L (fr)
NZ (1) NZ537818A (fr)
OA (1) OA12899A (fr)
PA (1) PA8577301A1 (fr)
PE (1) PE20040992A1 (fr)
PL (1) PL375553A1 (fr)
PT (1) PT1536782E (fr)
RS (1) RS20050078A (fr)
SI (1) SI1536782T1 (fr)
TN (1) TNSN05042A1 (fr)
TW (1) TW200404531A (fr)
UA (1) UA77329C2 (fr)
UY (1) UY27936A1 (fr)
WO (1) WO2004016259A1 (fr)
ZA (1) ZA200500369B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
BRPI0414347A (pt) * 2003-09-12 2006-11-07 Warner Lambert Co associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
WO2005030700A2 (fr) * 2003-09-25 2005-04-07 Warner-Lambert Company Llc Acides amines a affinite pour la proteine a2d
WO2005030184A2 (fr) 2003-09-25 2005-04-07 Warner-Lambert Company Llc Procedes de mise en oeuvre d'acides amines a affinite pour la proteine a2d
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
AU2005264036A1 (en) * 2004-07-09 2006-01-26 Warner-Lambert Company Llc Preparation of beta-amino acids having affinity for the alpha-2-delta protein
ITMI20041447A1 (it) * 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
JP2008512436A (ja) * 2004-09-07 2008-04-24 ファイザー・インク 片頭痛治療用の５−ＨＴ（１）受容体アゴニストとα２δリガンドの組み合わせ
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
RU2469715C2 (ru) * 2007-04-30 2012-12-20 Адолор Корпорейшн Композиции (-)-e-10-oh-nt и способы их синтеза и применения
WO2008132589A1 (fr) * 2007-05-01 2008-11-06 Pfizer Limited Combinaisons comprenant de la prégabaline
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
TWI531362B (zh) 2008-07-21 2016-05-01 艾爾康股份有限公司 具有治療劑遞送能力之眼科裝置
JP5786714B2 (ja) * 2010-07-30 2015-09-30 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
US8962831B2 (en) 2011-05-17 2015-02-24 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2012158795A1 (fr) 2011-05-17 2012-11-22 Principia Biopharma Inc. Dérivés de pyrazolopyrimidine utilisés comme inhibiteurs de tyrosine kinase
JP6068451B2 (ja) 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
WO2013084182A1 (fr) * 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Composition pharmaceutique comprenant un inhibiteur de l'enzyme pde4 et un agent analgésique
RS58956B1 (sr) 2012-09-10 2019-08-30 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
MX372673B (es) 2014-02-21 2020-03-25 Principia Biopharma Inc Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
ES2843323T3 (es) 2014-12-18 2021-07-16 Principia Biopharma Inc Tratamiento de pénfigo
EP3313839A1 (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc. Inhibiteurs de la tyrosine kinase
US20190231784A1 (en) 2016-06-29 2019-08-01 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR20220080179A (ko) 2019-10-14 2022-06-14 프린시피아 바이오파마, 인코퍼레이티드 (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 면역 혈소판 감소증을 치료하는 방법
TW202140484A (zh) 2020-01-22 2021-11-01 美商普林斯匹亞生物製藥公司 ２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）－１Ｈ－吡唑并［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈之晶形
CN114195661B (zh) * 2021-12-21 2023-12-22 苏州楚凯药业有限公司 一种苯磺酸米洛巴林的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2200184T7 (es) * 1996-07-24 2015-02-10 Warner-Lambert Company Llc Isobutilgaba y sus derivados para el tratamiento del dolor
KR20010033158A (ko) * 1997-12-16 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 1-치환-1-아미노메틸-시클로알칸 유도체 (=가바펜틴동족체), 그의 제조법 및 신경성 질환 치료에 있어서 그의용도
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
BR0113644A (pt) * 2000-08-30 2003-07-29 Lilly Icos Llc Usos do inibidor de pde5 no tratamento de enxaqueca
YU78803A (sh) * 2001-04-19 2006-08-17 Warner-Lambert Company Fuzija bicikličnih ili tricikličnih amino kiselina

Also Published As

Publication number Publication date
NZ537818A (en) 2007-07-27
CA2495433A1 (fr) 2004-02-26
SI1536782T1 (sl) 2007-08-31
GB0219024D0 (en) 2002-09-25
ZA200500369B (en) 2006-10-25
GEP20084366B (en) 2008-05-13
CN1674884A (zh) 2005-09-28
EA200500207A1 (ru) 2005-08-25
HRP20050136A2 (en) 2005-06-30
ECSP055593A (es) 2005-04-18
PT1536782E (pt) 2007-06-27
MA27381A1 (fr) 2005-06-01
TW200404531A (en) 2004-04-01
UA77329C2 (en) 2006-11-15
RS20050078A (sr) 2007-09-21
AR040871A1 (es) 2005-04-20
MXPA05001835A (es) 2005-09-30
OA12899A (en) 2006-10-13
PL375553A1 (en) 2005-11-28
PA8577301A1 (es) 2004-03-10
DE60313330T2 (de) 2008-01-03
EP1536782A1 (fr) 2005-06-08
EP1536782B1 (fr) 2007-04-18
IS7643A (is) 2005-01-12
WO2004016259A1 (fr) 2004-02-26
AU2003249476B2 (en) 2008-06-26
NO20050782L (no) 2005-04-08
DK1536782T3 (da) 2007-07-30
KR20050042154A (ko) 2005-05-04
ES2285230T3 (es) 2007-11-16
HN2003000247A (es) 2007-12-14
DE60313330D1 (de) 2007-05-31
ATE359775T1 (de) 2007-05-15
UY27936A1 (es) 2004-03-31
JP2006502139A (ja) 2006-01-19
EA007504B1 (ru) 2006-10-27
BR0313484A (pt) 2005-06-21
GT200300173A (es) 2007-03-29
IL166415A0 (en) 2006-01-15
KR20070009746A (ko) 2007-01-18
PE20040992A1 (es) 2004-12-29
AU2003249476A1 (en) 2004-03-03
AP2005003227A0 (en) 2005-03-31
CR7687A (es) 2005-07-08

Similar Documents

Publication Publication Date Title
TNSN05042A1 (fr) Association synergique d'un ligand de alpha -2- delta et d'un inhibiteur de pdev pour une utilisation dans le traitement de la douleur
MXPA05012880A (es) Inhibidores de complemento.
WO2003042246A3 (fr) Traitement medical
EA200400153A1 (ru) Бета-аминотетрагидроимидазо-(1,2-a)-пиразины и тетрагидротриазоло-(4,3-a)-пиразины как ингибиторы дипептидилпептидазы для лечения или предотвращения диабета
MY162110A (en) Caspase inhibitors containing isoxazoline ring
ATE553198T1 (de) Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
EP2295433A3 (fr) Inhibiteurs de JNK
PT1581235E (pt) Utilização de espongosina (2-metoxiadenoseína) para o tratamento de dor, em particular hiperalgesia
IL160523A0 (en) PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
MXPA04003365A (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina.
MY135237A (en) Mold inhibitor having reduced corrosiveness
CA3155887A1 (fr) Compositions de dentifrice comprenant un sel de bicarbonate et un acide amine neutre
UA88771C2 (ru) Ингибиторы протеасомы и способ их применения (варианты)
AU2019282132A8 (en) Compositions and methods for treating pancreatitis
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
MXPA06000652A (es) Sales alcalinas de inhibidores de bomba de protones.
PT1042288E (pt) Inibidores de tripeptidil peptidase
DOP2003000667A (es) Combinaciones sinergicas
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.
TW200642688A (en) New use of PDE7 inhibitors
WO2003075926A8 (fr) Utilisation d'inhibiteurs de la pompe a protons pour traiter des troubles des voies respiratoires
AU2002253445A8 (en) Synergistic composition of trans-tetracos-15-enoic acid and apocynin and use thereof
Nycander Interaction of cystatins with cysteine proteinases.
TH67418A (th) สารผสมผสานเสริมฤทธิ์กัน